转录组学在抗击结核病中的作用：聚焦生物标志物、卡介苗接种及免疫疗法。
The impact of transcriptomics on the fight against tuberculosis: focus on biomarkers, BCG vaccination, and immunotherapy.
作者信息
Zárate-Bladés Carlos Rodrigo, Silva Celio Lopes, Passos Geraldo A
机构信息
The Centre for Tuberculosis Research, Department of Biochemistry and Immunology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto SP, Brazil.
出版信息
Clin Dev Immunol. 2011;2011:192630. doi: 10.1155/2011/192630. Epub 2010 Dec 20.
In 1882 Robert Koch identified Mycobacterium tuberculosis as the causative agent of tuberculosis (TB), a disease as ancient as humanity. Although there has been more than 125 years of scientific effort aimed at understanding the disease, serious problems in TB persist that contribute to the estimated 1/3 of the world population infected with this pathogen. Nonetheless, during the first decade of the 21st century, there were new advances in the fight against TB. The development of high-throughput technologies is one of the major contributors to this advance, because it allows for a global vision of the biological phenomenon. This paper analyzes how transcriptomics are supporting the translation of basic research into therapies by resolving three key issues in the fight against TB: (a) the discovery of biomarkers, (b) the explanation of the variability of protection conferred by BCG vaccination, and (c) the development of new immunotherapeutic strategies to treat TB.
1882年，罗伯特·科赫确定结核分枝杆菌为结核病（TB）的病原体，结核病是一种与人类历史一样古老的疾病。尽管为了解这种疾病已经进行了超过125年的科学研究，但结核病仍然存在严重问题，这导致全球约三分之一的人口感染了这种病原体。然而，在21世纪的第一个十年里，抗击结核病取得了新进展。高通量技术的发展是这一进展的主要推动因素之一，因为它使人们能够从全球角度看待生物现象。本文分析了转录组学如何通过解决抗击结核病的三个关键问题，支持基础研究向治疗方法的转化：（a）生物标志物的发现；（b）卡介苗接种所提供保护的变异性的解释；（c）治疗结核病的新免疫治疗策略的开发。
Zotero 插件